by Alex Kadhim
Researchers identified ADGRG1 and CD86 as novel markers of tumor-reactive CD4+ T cells in solid tumors, enabling enrichment of neoantigen-specific lymphocytes for functional studies and...
by Alex Kadhim
A pooled analysis in advanced melanoma identifies stem-like and LAG-3-expressing CD8+ T cells, along with tumor-associated tertiary lymphoid structures, as key predictors of durable response to...
by Alex Kadhim
New research identifies a B cell–CD2 costimulatory pathway that enhances adoptive T-cell therapy, improving TIL and CAR-T cell function, metabolism, and tumor control in solid tumors. These...
by Alex Kadhim
Real-world Mayo Clinic data demonstrate the feasibility and effectiveness of tumor-infiltrating lymphocyte (TIL) therapy for metastatic melanoma, highlighting clinical outcomes, immune recovery,...
by ASTCT Talks
In this episode of ASTCT Talks, host Daniel Olson, MD, of the University of Chicago, is joined by Stephanie Goff, MD, of the National Cancer Institute (NCI), and Allison Betof, MD, PhD, of...
by Alex Kadhim
Reporting in Cancer Immunology Research, researchers have demonstrated that potent cytotoxic tumor-infiltrating lymphocytes (TILs) can be generated from immune-excluded chondrosarcomas using...